FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980938688> ?p ?o ?g. }

• W2980938688 abstract "Abstract Abstract 4482 Introduction: Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning (RIC) including radioimmunotherapy (RIT) with yttrium-90 ibritumomab tiuxetan is a potential salvage treatment for patients with advanced high-risk B-cell lymphoma. The influence of RIT combined with RIC on immune reconstitution after allogeneic HCT has not been evaluated. Methods: We compared data on immune reconstitution of 14 patients receiving allogeneic HCT after RIT-RIC at our institution from 2006 to 2008. Yttrium-90 ibritumomab tiuxetan as RIT and RIC with either fludarabine (30 mg/m2, day −8 to −4)/melphalan (140 mg/m2, day −3)/alemtuzumab (20 mg for related donors and 30 mg for unrelated donors, day −3 and −2) (n=7, FLU/MEL/AL-RIT group) or fludarabine (30 mg/m2, day −4 to −2)/2 Gy total body irradiation (day 0) (n=7, FLU/TBI-RIT group) were used. Immunosuppression consisted of cyclosporine A alone (FLU/MEL/AL-RIT group) or cyclosporine A combined with mycophenolate mofetil (FLU/TBI-RIT group). The results were compared to 14 patients in a concurrent control group with similar conditioning regimens without RIT (n=7, FLU/MEL (without alemtuzumab); n=7, FLU/TBI). Differences in engraftment and immune reconstitution were evaluated. Results: Diagnoses in the RIT groups were high-grade NHL (n=6), low-grade NHL (n=6) and CLL (n=2). In the control groups diagnoses were high-grade NHL (n=4), acute leukemia (n=6), MDS (n=1), multiple myeloma (n=1), Hodgkin's lymphoma (n=1) and CLL (n=1). Neutrophil engraftment (>500/μl) was observed after a median of 20 days (range 13–26) in the FLU/MEL/AL-RIT-group compared to 15 days (range 11–21) in the control group (p=0.11). After a median of 13 days (range 7–17) and 12 days (range 8–27) neutrophil engraftment was noted in the FLU/TBI-RIT group and control group, respectively (p=0.40). Median time to thrombocyte engraftment (>20,000/μl) was 11 days (range 8–42) in the FLU/MEL/AL-RIT-group and 21 days (range 5–29) in the control group (p=0.81). After a median of 10 days (range 7–16) and 11 days (range 10–35) thrombocyte engraftment was noted in the FLU/TBI-RIT group and control group, respectively (p=0.23). Immune reconstitution in the four groups is shown in Table 1: Regeneration of CD3+8+ T-cells on day +100 and day +500 was significantly (p<0.10) reduced in the FLU/MEL/AL-RIT group compared to the FLU/MEL control group (p=0.08 and p=0.09) while no difference was observed between the FLU/TBI-RIT and the FLU/TBI group. No significant long-term difference in recovery of the CD19+ B-cells was observed although early B-cell levels on day +100 were reduced in the RIT groups. Conclusion: Not the use of yttrium-90 ibritumomab tiuxetan alone but its combination with alemtuzumab leads to a significantly slower immune reconstitution after allogeneic HCT. Disclosures: Off Label Use: Off-label conditioning regimen." @default.
• W2980938688 created "2019-10-25" @default.
• W2980938688 creator A5020985831 @default.
• W2980938688 creator A5023183268 @default.
• W2980938688 creator A5033322659 @default.
• W2980938688 creator A5039469115 @default.
• W2980938688 creator A5047060286 @default.
• W2980938688 creator A5065062556 @default.
• W2980938688 creator A5066624700 @default.
• W2980938688 date "2012-11-16" @default.
• W2980938688 modified "2023-09-27" @default.
• W2980938688 title "Delayed Immune Reconstitution After Allogeneic Hematopoietic Cell Transplantation with Yttrium-90 Ibritumomab Tiuxetan-Based Reduced-Intensity Conditioning" @default.
• W2980938688 doi "https://doi.org/10.1182/blood.v120.21.4482.4482" @default.
• W2980938688 hasPublicationYear "2012" @default.
• W2980938688 type Work @default.
• W2980938688 sameAs 2980938688 @default.
• W2980938688 citedByCount "0" @default.
• W2980938688 crossrefType "journal-article" @default.
• W2980938688 hasAuthorship W2980938688A5020985831 @default.
• W2980938688 hasAuthorship W2980938688A5023183268 @default.
• W2980938688 hasAuthorship W2980938688A5033322659 @default.
• W2980938688 hasAuthorship W2980938688A5039469115 @default.
• W2980938688 hasAuthorship W2980938688A5047060286 @default.
• W2980938688 hasAuthorship W2980938688A5065062556 @default.
• W2980938688 hasAuthorship W2980938688A5066624700 @default.
• W2980938688 hasConcept C126322002 @default.
• W2980938688 hasConcept C159654299 @default.
• W2980938688 hasConcept C203014093 @default.
• W2980938688 hasConcept C2776146153 @default.
• W2980938688 hasConcept C2776694085 @default.
• W2980938688 hasConcept C2776755627 @default.
• W2980938688 hasConcept C2778515704 @default.
• W2980938688 hasConcept C2778684742 @default.
• W2980938688 hasConcept C2778880498 @default.
• W2980938688 hasConcept C2779015954 @default.
• W2980938688 hasConcept C2779263901 @default.
• W2980938688 hasConcept C2911091166 @default.
• W2980938688 hasConcept C542903549 @default.
• W2980938688 hasConcept C71924100 @default.
• W2980938688 hasConcept C90924648 @default.
• W2980938688 hasConceptScore W2980938688C126322002 @default.
• W2980938688 hasConceptScore W2980938688C159654299 @default.
• W2980938688 hasConceptScore W2980938688C203014093 @default.
• W2980938688 hasConceptScore W2980938688C2776146153 @default.
• W2980938688 hasConceptScore W2980938688C2776694085 @default.
• W2980938688 hasConceptScore W2980938688C2776755627 @default.
• W2980938688 hasConceptScore W2980938688C2778515704 @default.
• W2980938688 hasConceptScore W2980938688C2778684742 @default.
• W2980938688 hasConceptScore W2980938688C2778880498 @default.
• W2980938688 hasConceptScore W2980938688C2779015954 @default.
• W2980938688 hasConceptScore W2980938688C2779263901 @default.
• W2980938688 hasConceptScore W2980938688C2911091166 @default.
• W2980938688 hasConceptScore W2980938688C542903549 @default.
• W2980938688 hasConceptScore W2980938688C71924100 @default.
• W2980938688 hasConceptScore W2980938688C90924648 @default.
• W2980938688 hasLocation W29809386881 @default.
• W2980938688 hasOpenAccess W2980938688 @default.
• W2980938688 hasPrimaryLocation W29809386881 @default.
• W2980938688 hasRelatedWork W2032386717 @default.
• W2980938688 hasRelatedWork W2164533071 @default.
• W2980938688 hasRelatedWork W2287434901 @default.
• W2980938688 hasRelatedWork W2287774911 @default.
• W2980938688 hasRelatedWork W2345395215 @default.
• W2980938688 hasRelatedWork W2531994769 @default.
• W2980938688 hasRelatedWork W2546313647 @default.
• W2980938688 hasRelatedWork W2563857296 @default.
• W2980938688 hasRelatedWork W2570427855 @default.
• W2980938688 hasRelatedWork W2580210165 @default.
• W2980938688 hasRelatedWork W2580594058 @default.
• W2980938688 hasRelatedWork W2586381253 @default.
• W2980938688 hasRelatedWork W2587399432 @default.
• W2980938688 hasRelatedWork W2589042404 @default.
• W2980938688 hasRelatedWork W2895136172 @default.
• W2980938688 hasRelatedWork W2972799950 @default.
• W2980938688 hasRelatedWork W2991687763 @default.
• W2980938688 hasRelatedWork W3045133529 @default.
• W2980938688 hasRelatedWork W3139359447 @default.
• W2980938688 hasRelatedWork W299417976 @default.
• W2980938688 isParatext "false" @default.
• W2980938688 isRetracted "false" @default.
• W2980938688 magId "2980938688" @default.
• W2980938688 workType "article" @default.